US EditionPublished • loading... • Updated
What's Going On With Neurocrine Biosciences Stock Tuesday? - Neurocrine Biosciences (NASDAQ:NBIX)
The largest placebo-controlled trial in dyskinetic cerebral palsy showed valbenazine did not improve chorea; adverse events matched known safety profiles, Neurocrine reported.
- On Dec. 22, 2025, Neurocrine Biosciences announced its Phase 3 KINECT‑DCP study of valbenazine in pediatric and adult dyskinetic cerebral palsy participants failed to meet primary and key secondary endpoints.
- The study was designed to measure chorea improvement as the Phase 3 KINECT‑DCP study used a randomized, double‑blind, placebo‑controlled design, the largest trial completed in DCP.
- Participants aged six to 70 were randomized to valbenazine or placebo, then could enter an open‑label extension where all received valbenazine; adverse events aligned with its established safety profile.
- Neurocrine will present full results at a scientific meeting; Sanjay Keswani called the outcome disappointing and noted no approved treatments for DCP, while the company said NBI‑1065890 enters Phase II next year.
- DCP affects about three per 1,000 U.S. children and accounts for approximately 15% of CP cases, while valbenazine holds FDA approvals in 2017 and 2023, Neurocrine said.
Insights by Ground AI
25 Articles
25 Articles
Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints
Neurocrine Biosciences has reported that its Phase III trial assessing the selective vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine, for dyskinetic cerebral palsy in paediatric and adult populations, failed to achieve the endpoints.The post Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources25
Leaning Left1Leaning Right0Center9Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
